Drug Burden Index in older adults: theoretical and practical issues

Lisa Kouladjian1
Danijela Gnjidic1,2
Timothy F Chen2
Arduino A Mangoni3
Sarah N Hilmer1
1Sydney Medical School, University of Sydney, Kolling Institute of Medical Research and Departments of Clinical Pharmacology and Aged Care, Royal North Shore Hospital, 2Faculty of Pharmacy, University of Sydney, Sydney, NSW, 3Department of Clinical Pharmacology, School of Medicine, Flinders University and Flinders Medical Centre, Bedford Park, SA, Australia

Clinical scenario
An 81-year old Caucasian female presents with complaints of a dry mouth and morning sedation. The patient lives alone in a dwelling adjacent to her daughter and son-in-law, and has also noted a decreased ability to complete her daily activities due to fatigue. Her past medical history includes hypertension, urinary incontinence, insomnia, and osteoarthritic pain. Her medications include irbesartan 300 mg daily, darifenacin 15 mg daily, temazepam 7.5 mg at night, and acetaminophen/codeine 300 mg/15 mg two tablets three times daily. Her physician referred her for medication review by a pharmacist as part of the Medication Therapy Management pharmacy practice program.

Introduction
The proportion of older people in the population is increasing globally. It is estimated that by 2050, 22% of the total world’s population will be aged over 60 years. Current evidence shows that older people are the largest per capita consumers of medications, especially the oldest old (aged over 84 years). The rise in polypharmacy (use of five or more medications) is driven by the growth of an aging and increasingly frail population with multiple chronic diseases.

Medication management for older adults is fast becoming a challenge for health care professionals, and establishing the balance between the benefits and risks of medication use is often difficult. Many studies have highlighted the key role of regular assessment of medication regimens by primary health care professionals. According to the US Center for Medicare and Medicaid Services, it is estimated that polypharmacy costs US$50 billion annually, and hence better evidence-based management approaches are essential to overcome polypharmacy and optimize medication use in older adults.

Some of the most commonly prescribed medications in older people include those with anticholinergic (antimuscarinic) and sedative effects, and inappropriate use of these medications is associated with adverse outcomes. For example, studies in older adults have shown that older adults using anticholinergics are more likely to experience cognitive impairment and increased risk of falls. Similarly, sedative medications can lead to sleep-related problems and decreased daytime alertness. Therefore, deprescribing and pharmacological risk assessment tools are essential to overcome polypharmacy and optimize medication use in older adults.

Abstract: Anticholinergic and sedative medications are commonly used in older adults and are associated with adverse clinical outcomes. The Drug Burden Index was developed to measure the cumulative exposure to these medications in older adults and its impact on physical and cognitive function. This narrative review discusses the research and clinical applications of the Drug Burden Index, and its advantages and limitations, compared with other pharmacologically developed measures of high-risk prescribing.

Keywords: Drug Burden Index, anticholinergics, sedative medications, high-risk prescribing, older adults, pharmacological risk assessment tools, deprescribing

Clinical Interventions in Aging 2014:9 1503–1515

Correspondence: Lisa Kouladjian
Clinical Pharmacology and Aged Care, Level 12 Kolling Building, Royal North Shore Hospital, Reserve Road, St Leonards, NSW, Australia 2065
Tel +61 2 9926 4934
Fax +61 2 9926 4053
Email lisa.kouladjian@sydney.edu.au
adults have concluded that high use of anticholinergic medications is associated with poor cognitive function and functional impairments. Many measures have been established to assess exposure to these types of medication in older adults, and each measure has its own role, advantages, and disadvantages.

This narrative review aims to evaluate and summarize the theoretical and practical aspects of the Drug Burden Index (DBI), a pharmacological risk assessment tool that measures the burden of anticholinergic and sedative medications in older adults. Specifically, it analyzes the effects of these medications in older adults, summarizes the development of the DBI, discusses the evidence supporting its utilization in practice, and compares the DBI with other pharmacologically developed models that measure anticholinergic or sedative exposure in older adults.

Search strategy
A search was conducted in Medline and PubMed using the following search terms: “Drug Burden Index”, “anticholinergics”, “sedatives”, “scales”, “index”, “burden”, “model”, “older people”, “aged”, and “aging”. Published articles were reviewed starting from January 2000, and citations in reviews and research articles were also searched.

Impact of anticholinergic and sedative medications on older adults
Anticholinergic and sedative medications are used widely among older adults. Overuse of these medications has been associated with adverse drug events, some of which may limit physical and cognitive function. The muscarinic receptor blocking action of anticholinergics may cause dry mouth, constipation, blurred vision, increased heart rate, and confusion. Benzodiazepines, antipsychotics, antidepressants, opioid analgesics, and other drugs acting on the central nervous system can cause sedation, delirium, and impaired functional and cognitive status. Anticholinergic and sedative medications are prescribed in older adults to treat medical conditions that usually occur later in life, such as urinary incontinence, sleep and pain disorders, dementia, chronic obstructive pulmonary disease, and mental illness. However, evidence suggests that often the benefits do not justify the risks for some medications in older adults, for example chronic sedative medication use for insomnia. There is also significant evidence of an association between anticholinergic medications and neuropsychiatric adverse drug events in older adults. Evidence further suggests that clinicians may be less aware that some medications used in older adults, that are not prescribed for their anticholinergic properties, have anticholinergic effects, peripherally and centrally; for example, amitriptyline or doxepin for major depressive disorder. This is not surprising, as more than 600 drugs have been shown to have some degree of anticholinergic activity in vitro, with 14 of the 25 medications most commonly prescribed for older adults (in Italy) having detectable anticholinergic effects centrally. Furthermore, there is no gold standard definition for medications with anticholinergic effects for clinicians to refer to. As a consequence of multimorbidity and older age, many medications that act on the central nervous system and have sedative properties may result in depressive symptoms, impaired muscle strength, and worsened cognition and respiratory depression. This in turn may result in falls, fractures, hospitalization, and institutionalization. Additionally, several anticholinergic medications also have sedative properties, for example, olanzapine or quetiapine, making older people who are using medications from both classes, and who are already at risk from polypharmacy, more vulnerable to adverse drug events and their consequences.

Development of the Drug Burden Index
The DBI was developed and published in 2007 by Hilmer et al and measures the effect of cumulative exposure to both anticholinergic and sedative medications on physical and cognitive function in older adults. The DBI calculation was also intended to be an evidence-based risk assessment tool to guide prescribing in older people. It was proposed that the DBI calculation could be implemented in prescribing software to inform prescribers of the likely functional implications of an older patient’s total exposure to these high-risk medications. A pharmacological equation was postulated by maintaining a classical dose–response relationship (Figure 1). The researchers hypothesized that the cumulative effect of anticholinergic and sedative medications would be linear, and a simple additive model was used to establish the total anticholinergic and sedative burden. The dose of each anticholinergic and sedative medication was used to determine a score from 0 to 1 for each drug in these classes. The relationship between an individual’s DBI and their physical and cognitive performance was then evaluated in a cohort of community-dwelling older adults. It was shown that each additional unit of DBI had a negative effect on physical function similar to that of three additional physical morbidities.
Mathematically, the drug burden is calculated for every patient according to the formula: \( \text{Total Drug Burden} = B_{AC} + B_S \), where \( B \) indicates burden, \( AC \) indicates anticholinergic, and \( S \) indicates sedative. Assuming that the anticholinergic and sedative effects of different drugs are additive in a linear fashion, \( B_{AC} \) and \( B_S \) may be proportional to a linear additive model of pharmacological effect (\( E \)). This led to the formation of the equation:

\[
\frac{E}{\alpha} = \sum \frac{D}{D + DR_{50}}
\]

where \( \alpha \) is a proportionality constant, \( D \) is the daily dose, and \( DR_{50} \) is the daily dose required to achieve 50% of maximal contributory effect at steady state. Furthermore, as the general \( DR_{50} \) of anticholinergic and sedative effect is not identifiable and doses need to be normalized, the \( DR_{50} \) was estimated as the minimum recommended daily dose (\( \delta \)) as listed by the medication product information approved by the US Food and Drug Administration (Table 1). As there are some differences between countries in the \( \delta \) of medications, subsequent studies using the DBI have used the minimum recommended daily dose in the study population setting. Besides being influenced by regulatory factors, the minimum daily dose accounts for additional factors that may influence drug effects such as genetics, ethnicity, diet, and environment. This flexibility allows the tool to be tailored for specific countries, for example, diazepam has a minimum registered/licensed dose of 4 mg in the USA and 5 mg in Australia.

The DBI is one of the few cumulative medication exposure measures that considers the dose. Furthermore, medications that are reported to be both sedative and anticholinergic are considered as anticholinergic to prevent double entries,

### Table 1 Example of mathematical calculation of the Drug Burden Index (using clinical scenario)

<table>
<thead>
<tr>
<th>Medications in clinical scenario</th>
<th>Daily dose (D)</th>
<th>Minimum recommended daily dose (( \delta ))</th>
<th>Individual DBI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Irbesartan 300 mg, daily</td>
<td>300 mg</td>
<td>75 mg (no anticholinergic or sedative effects)</td>
<td>0</td>
</tr>
<tr>
<td>Darifenacin 15 mg, daily</td>
<td>15 mg</td>
<td>7.5 mg (anticholinergic effects)</td>
<td>0.67</td>
</tr>
<tr>
<td>Temazepam 7.5 mg, at night</td>
<td>7.5 mg</td>
<td>7.5 mg (sedative effects)</td>
<td>0.50</td>
</tr>
<tr>
<td>Acetaminophen 300 mg, 2 tablets tds</td>
<td>1,800 mg</td>
<td>300 mg (no anticholinergic or sedative effects)</td>
<td>0</td>
</tr>
<tr>
<td>Codeine 15 mg, 2 tablets tds</td>
<td>90 mg</td>
<td>120 mg (sedative effects)</td>
<td>0.43</td>
</tr>
</tbody>
</table>

**Total DBI calculation**

\[
DBI = \sum \frac{D}{D + \delta}
\]

**Notes:** This is an example of a medication regimen for an older adult in the USA; minimum daily dose as recommended by the US Food and Drug Administration.

**Abbreviations:** tds, three times a day; DBI, Drug Burden Index.
and therefore a separate anticholinergic DBI can be calculated from the DBI. Originally, medications with clinically significant anticholinergic or sedative effects were identified by means of Mosby’s Drug Consult and the Physicians’ Desk Reference. Further observational studies have used various country-specific resources to identify these high-risk medications with similar findings, reflecting the adaptability of the equation to the investigation setting.

**Validation studies of the Drug Burden Index**

Increasing DBI exposure has been associated with poorer physical function, frailty, and falls. With regard to hospitalization, a higher DBI has also been associated with increased hospital days, increased hospitalization for delirium, and readmission to hospital (Table 2).

There have been mixed reports on the association of DBI with mortality and cognition. One study conducted in people living in residential care facilities in Australia reported a non-significant association between high DBI and mortality. A study conducted in the Netherlands on older patients admitted to hospital with hip fractures showed a significant univariate but not multivariate association of increasing anticholinergic component of the DBI with one-year mortality. A population-based study of older people in New Zealand found that DBI exposure increased the risk of mortality, and a study in Finland found an association of high DBI exposure with mortality in people with and without Alzheimer’s disease.

Regarding cognition, the original validation study in the USA found that increasing DBI was associated with impaired cognition in community-dwelling older people when measured using the digit symbol substitution test; however, no associations were observed between DBI and cognition in a cohort of community-dwelling older men in Australia. Observational studies conducted in older adults from different international settings generate relatively consistent findings, confirming a trend towards prescribing of these high-risk medications and poorer physical function outcomes in older adults.

**Utility of the Drug Burden Index in practice**

Currently, most studies of DBI in clinical practice have been observational. Limited studies have investigated associations between pharmaceutical service provision, prescribing outcomes, and functional outcomes in older adults (Table 3). In Australia, Home Medicine Review and Residential Medication Management Review are community-based collaborative services provided by general practitioners and pharmacists and fall under the Commonwealth-funded Medication Management Initiatives. Two retrospective analyses have investigated DBI associations before and after Home Medicine Review and Residential Medication Management Review services, respectively. Castelino et al concluded that the recommendations provided by a pharmacist as part of the service resulted in a significant reduction in the sum total of DBI scores for all patients. Similarly, Nishtala et al found that DBI scores of participants were significantly lower after the pharmacist-led Residential Medication Management Review intervention. In both studies, the DBI was used as a screening or evaluation tool to measure service provision, the quality of pharmacists’ recommendations, and prescribing changes by general practitioners following uptake of recommendations. As these studies were retrospective in nature, it was not possible to assess changes in function and cognition of subjects. Additionally, these studies suggest that the DBI may be used to evaluate medication therapy management services, alongside other markers such as polypharmacy (five or more medications), hyperpolypharmacy (ten or more medications), or use of psychotropic medications (Omnibus Budget Reconciliation Act 1987) to demonstrate prescribing appropriateness and predict functional outcomes in older adults.

To date, only one interventional study has been conducted in the primary care setting using the DBI. This was a pilot cluster, randomized controlled trial in people aged ≥70 years living in retirement villages. For participants in the intervention group general practitioners were provided with patient-specific information on their patient’s DBI and its health/functional implications, and were asked to consider cessation or dose reduction of anticholinergic and sedative medications contributing to DBI. For those in the control group, general practitioners were provided with their patient’s medication list only. Amongst those with DBI >0 at baseline, DBI was reduced in 32% of the intervention group and in 19% of control participants. However, this approach only targeted general practitioners, and may reflect the poor effectiveness of the intervention design. Recent reviews state the lack of evidence for clinical effectiveness and sustainability of varying interventions to reduce polypharmacy. Further studies have demonstrated that multidisciplinary interventions using various intervention combinations (such as educational material, computerized support systems, medication reviews by pharmacists) are more effective than single interventions, such as that used...
### Table 2: Evidence supporting the association of the Drug Burden Index with outcomes: cross-sectional and longitudinal studies categorized by participant setting

<table>
<thead>
<tr>
<th>Study setting, population age</th>
<th>Country (n)</th>
<th>Prevalence % DBI &gt;0 or mean (± SD)</th>
<th>DBI association with outcomes</th>
<th>Resource used to identify minimum effective dose (δ) of medications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cross-sectional, community-dwelling older adults</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>70–79 years</td>
<td>USA (3,075)</td>
<td>0.18 ± 0.35</td>
<td>DBI was associated with poorer physical function and cognition¹</td>
<td>FDA</td>
</tr>
<tr>
<td>≥70 years⁹, ¹⁰</td>
<td>Australia (1,705)</td>
<td>0.18±0.35</td>
<td>Higher DBI was associated with poorer physical performance and functional status²⁴</td>
<td>TGA</td>
</tr>
<tr>
<td>≥70 years⁹, ¹⁰</td>
<td>Australia (1,662)</td>
<td>Robust 20.1% Pre frail 29.7% Frail 45.5%</td>
<td>Higher DBI may contribute to frailty²⁷</td>
<td>TGA</td>
</tr>
<tr>
<td>≥70 years⁹, ¹⁰</td>
<td>Australia (987)</td>
<td>27.8%</td>
<td>DBI was not associated with limitations on objective cognitive measures or with cognitive impairment²⁵</td>
<td>TGA</td>
</tr>
<tr>
<td>≥75 years</td>
<td>Finland (700)</td>
<td>36.7%</td>
<td>DBI was associated with functional impairment²⁶</td>
<td>Pharmaca Fennica</td>
</tr>
<tr>
<td>≥75 years</td>
<td>Finland (339)</td>
<td>37.5%</td>
<td>Exposure to DBI medications was associated with a greater use of hospital days⁸³</td>
<td>Pharmaca Fennica</td>
</tr>
<tr>
<td>Admitted to geriatric medicine units, ≥60 years</td>
<td>UK (362)</td>
<td>Median (IQR) 0.48 (0.00–1.00)</td>
<td>Higher DBI scores on admission were independently associated with length of hospital stay and lower scores in functional measures⁶⁶</td>
<td>BNF</td>
</tr>
<tr>
<td>Cross-sectional, residential aged care or hospitalized older adults</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥70 years</td>
<td>Australia (602)</td>
<td>69.9%</td>
<td>DBI was only associated with impairment in balance and not with physical function²¹</td>
<td>TGA sourced from MIMS²⁵</td>
</tr>
<tr>
<td>≥70 years</td>
<td>Australia (115)</td>
<td>0.24±0.40</td>
<td>DBI was significantly and independently associated with falls in older people²⁹</td>
<td>TGA</td>
</tr>
<tr>
<td>≥65 years</td>
<td>The Netherlands (71)</td>
<td>Median (range) for ACh component 0.00 (0.00–1.75)</td>
<td>ACh-DBI was significantly associated with 3-month and one-year mortality²⁸</td>
<td>BNF</td>
</tr>
<tr>
<td>≥65 years</td>
<td>Australia (226)</td>
<td>78.8%</td>
<td>A DBI &gt;0 was associated with poorer self-reported quality of life outcomes⁶⁶</td>
<td>N/A</td>
</tr>
<tr>
<td>≥65 years⁷⁰, ⁷¹</td>
<td>USA (112)</td>
<td>N/A</td>
<td>High DBI scores were associated with poor clinical outcomes and longer lengths of hospital stay⁶⁰</td>
<td>Physicians’ Desk Reference²² and product information for individual drugs</td>
</tr>
<tr>
<td>Longitudinal, community-dwelling</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>70–79 years</td>
<td>USA (2,172)</td>
<td>34% At 5 years, 29%</td>
<td>Increased exposure to high DBI medications was associated independently with lower physical function over 5 years⁷⁷</td>
<td>FDA</td>
</tr>
<tr>
<td>Outpatient clinics, ≥60 years</td>
<td>Canada (102)</td>
<td>0.1±0.2 At one year, 0.6±0.2</td>
<td>An increase in the ACh-DBI correlated with poorer delayed memory performance⁹⁸</td>
<td>CPS</td>
</tr>
<tr>
<td>(ACh component of DBI used) Data extracted from pharmaceutical claims data of older people, ≥65 years</td>
<td>New Zealand (531,129)</td>
<td>31.8%</td>
<td>Anticholinergic exposure as measured by the ACh-DBI was prominent in the population, even amongst users of acetylcholinesterase inhibitors⁹⁹</td>
<td>Medsafe</td>
</tr>
</tbody>
</table>

(Continued)
Conclusion, these studies demonstrate the need for further research into multidisciplinary and multifactorial interventions using the DBI to evaluate prescribing and functional outcomes in older adults.

Theoretical aspects of the Drug Burden Index

Given its novelty and adaptability, the DBI has many theoretical applications in various settings for evaluating appropriate prescribing of anticholinergic and sedative medications in older adults. The original study by Hilmer et al. suggested that the DBI “by means of prescribing software” can inform clinicians of the implications of these high-risk medications in older people. Computerized decision support systems and computerized advice on drug dosage have been shown to improve prescribing practices, but have a mixed impact on patient outcomes. A recent meta-analysis concluded that electronic decision support systems that provided recommendations to both patients and clinicians may improve the success of interventions. Currently, the DBI is being developed as a software for use by pharmacists and general practitioners during the medication review process.

Furthermore, as the DBI has been validated across a number of countries, there may be many international applications of the DBI. Faure et al. suggested that standardizing the DBI calculation with the defined daily dose, as determined by the World Health Organization, would result in a universal quality indicator in drug management, ie, the “international DBI”. While there are concerns about the validity of the defined daily dose as an estimate of DR<sub>50</sub>, an international DBI would allow comparison of anticholinergic and sedative medication exposure and clinical outcomes in older patients globally, and could be applied to developing countries without national formularies.

Considerations when interpreting the Drug Burden Index

Like other pharmacological-based scales, the DBI has various limitations which must be considered when applying the tool in clinical settings. As discussed in the literature, it is difficult to determine exactly what constitutes an anticholinergic or sedative medication. There is no consensus on how to define an anticholinergic drug. Several scales have been developed by consensus panels and expert opinion. This may be difficult to justify unless the method used to arrive at consensus (for example, the Delphi method) is clearly stated for the purpose.
## Table 3: Studies of the Drug Burden Index in clinical practice

<table>
<thead>
<tr>
<th>Study setting, population age</th>
<th>Country (n)</th>
<th>Intervention or audit</th>
<th>DBI score at baseline and post-intervention or audit</th>
<th>DBI association with outcomes</th>
<th>Resource used to identify minimum effective dose (δ) of medications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Residential aged care home patients, ≥65 years</td>
<td>Australia (500)</td>
<td>RMMR&lt;sup&gt;23&lt;/sup&gt;</td>
<td>Median (IQR) Pre 0.50 (0–1.0) Post 0.33 (0–0.67)</td>
<td>RMMR intervention resulted in a statistically significant decrease in median DBI score&lt;sup&gt;35&lt;/sup&gt;</td>
<td>FDA</td>
</tr>
<tr>
<td>Community-dwelling older people, ≥65 years</td>
<td>Australia (372)</td>
<td>HMR&lt;sup&gt;33&lt;/sup&gt;</td>
<td>Median (IQR) Pre 0.50 (0–0.89) Post 0.22 (0–0.66)</td>
<td>Statistically significant decrease in the total DBI scores for all patients receiving an HMR service&lt;sup&gt;34&lt;/sup&gt;</td>
<td>FDA</td>
</tr>
<tr>
<td>Self-care retirement village older adults, ≥70 years</td>
<td>Australia (115)</td>
<td>Intervention targeting GP prescribing practices</td>
<td>Prevalence % DBI &gt;0, pre, post; Intervention group 33%, 32% Control group 53%, 19%</td>
<td>Intervention did not achieve anticipated outcomes. DBI decreased in both control and intervention groups&lt;sup&gt;37&lt;/sup&gt;</td>
<td>TGA</td>
</tr>
<tr>
<td>Hospitalized patients, ≥65 years</td>
<td>Australia (329)</td>
<td>Retrospective audit of medical records</td>
<td>Mean (95% CI) On admission 0.41 (0.34–0.47) On discharge 0.36 (0.30–0.41)</td>
<td>DBI was associated with an increased risk of hospital admission for delirium&lt;sup&gt;92&lt;/sup&gt;</td>
<td>TGA sourced from the MIMS&lt;sup&gt;95&lt;/sup&gt;</td>
</tr>
<tr>
<td>Hospitalized patients, ≥65 years</td>
<td>USA (229)</td>
<td>Retrospective audit of medical records</td>
<td>Mean ± SD On admission 1.00±0.92 On readmission 1.55±1.26</td>
<td>DBI scores were higher in patients readmitted to hospital&lt;sup&gt;93&lt;/sup&gt;</td>
<td>FDA</td>
</tr>
</tbody>
</table>

**Abbreviations:** DBI, Drug Burden Index; IQR, interquartile range; CI, confidence interval; SD, standard deviation; FDA, US Food and Drug Administration; TGA, Therapeutic Goods Administration of Australia; MIMS, Monthly Index of Medical Specialties; RMMR, Residential Medication Management Review; HMR, Home Medicine Review; GP, general practitioner.
investigated, and conflicts of interest are put forward, so as not to introduce bias to the outcome.\textsuperscript{48} The DBI uses the drug monograph to determine whether a drug has an anticholinergic or sedative effect by considering aspects of the pharmacology and side effect profiles. However, this method is also subject to interpretation bias. For example, anticholinesterases do not form part of the anticholinergic component of the DBI, but are included in the sedative component, and hence may cause confusion when calculating the DBI for a patient.

In terms of the calculation itself, the $DR_{50}$ is estimated as the minimum efficacious dose according to the approved product information. However, it does not take into account the specific indication nor interpatient pharmacokinetic or pharmacodynamic variations. This estimate is based on the regulatory principle that a registered dose must have some efficacy and that the minimum dose is likely to have less than maximal efficacy. The minimum recommended daily dose ($\delta$) was used as an estimate of the dose needed to achieve 50% of the maximum effect. The accuracy of the estimate of minimum efficacious dose may differ among drugs and subjects with different pharmacokinetic and pharmacodynamic characteristics. The DBI also assumes a linear dose-response relationship between drug classes. All medications with clinically relevant sedative or anticholinergic properties are considered equivalent, which may overestimate or underestimate the effect of the medication on the patient clinically.

Furthermore, previous studies considering the DBI have excluded the use of “as required” medications. Estimates of exposure to different dosing forms of medications (topical creams, eye drops, patches) have also not been clearly explained. This again may overestimate or underestimate the use of the anticholinergic or sedative medication of interest.

Drug response varies with basic physiological and pharmacological factors such as genetic variations, gender variations, and ethnicity. Additionally, in older adult populations, factors such as multimorbidity, polypharmacy, changes in organ function (such as liver or renal clearance), and frailty need to be considered when calculating medication burden.\textsuperscript{49} None of these factors are accounted for by the DBI calculation. Validation studies conducted in various countries and settings have demonstrated a wide range of prevalence of exposure to DBI medications, from 20% to 79% (Table 2). This variability may be related to varying definitions of anticholinergic and sedative medications sourced from monographs in different countries, specific sociodemographic or health status characteristics of participants, and factors related to the health care system influencing prescription of these medications. Furthermore, modifications to the DBI calculation may limit the validity and interpretation of the tool with important clinical outcomes. A recent study\textsuperscript{50} used a modified DBI calculation to conclude that higher DBI scores were associated with poor clinical outcomes and longer lengths of hospital stay. However, this study did not comment on associations with these clinical outcomes if the calculation was kept consistent with previous studies. The modified DBI may lead to overestimation or underestimation of the association of anticholinergic and sedative medication burden with important clinical outcomes in older adults.

Finally, as previously described, the evidence for the external validity and clinical applicability of the DBI is from observational studies and one pilot interventional study. Furthermore, several studies by Gnjidic et al\textsuperscript{23,27,32} were conducted in older male adults, and extrapolating data to females may be limited due to the differences in prescribing medications and variations in disease prevalence, functional impairment, and frailty between sexes.

**Comparison of Drug Burden Index with other evidence-based pharmacological tools**

Several measures of inappropriate prescribing have been developed with research on its prevalence, its association with adverse outcomes, and interventions to reduce this type of medication exposure. Various explicit and implicit inappropriate medication use scales, such as the Beers criteria,\textsuperscript{51} STOPP/START (Screening Tool of Older Person’s Prescriptions/Screening Tool to Alert doctors to Right Treatment) criteria,\textsuperscript{52,53} Medication Appropriateness Index,\textsuperscript{54,55} and Australian Indicators,\textsuperscript{56,57} are primarily used as general prescribing indicator tools across all medication classes rather than specifically with anticholinergic and sedative medications. Several other scales have been developed for evaluating exposure to anticholinergic or sedative medications alone. Examples of the anticholinergic scales include the Anticholinergic Drug Scale,\textsuperscript{58} the Anticholinergic Burden Classification,\textsuperscript{59} Clinician-rated Anticholinergic Score,\textsuperscript{60} Anticholinergic Risk Scale,\textsuperscript{61} Anticholinergic Activity Scale,\textsuperscript{62} Anticholinergic Load Scale,\textsuperscript{63} and Anticholinergic Cognitive Burden Scale,\textsuperscript{64} whilst the scales to determine the cumulative effects of taking multiple medications with sedative properties include the Sedative Load Model,\textsuperscript{65,66} the Sloane Model,\textsuperscript{67} the Central Nervous System Drug Model,\textsuperscript{68-70} and the Antipsychotic Monitoring Tool.\textsuperscript{71} However, when it comes to which scale or pharmacological indicator tool to apply for an older adult
to make a decision related to medication management in clinical practice, selecting the right tool for the individual patient situation is challenging for health care professionals. Each anticholinergic and sedative pharmacological tool has specific advantages and disadvantages based on the original study objectives and populations. Furthermore, only a few scales have been used in randomized controlled trials to determine prescribing outcomes in older adults.\textsuperscript{37-72}

There is considerable variation among the anticholinergic scales\textsuperscript{58} which is not surprising since the methodologies used to calculate and develop these scales vary significantly (Table 4). Additionally, a recent study concluded that there was poor agreement between the Anticholinergic Drug Scale, Anticholinergic Risk Scale, and Anticholinergic Cognitive Burden Scale, and suggested the scales could not be applied to varying study settings unless consistently updated.\textsuperscript{73} Furthermore, it has been proposed that a definitive international list of anticholinergic medications is important to build credible screening tools and to translate research with these scales to associations with clinical outcomes in older adults.\textsuperscript{46} However, establishing this “definitive” list would be difficult, as there are conflicting data in the literature on what constitutes an anticholinergic drug. Compiling such a list would require standardization of the anticholinergic effects in a typical older adult who has varied pharmacological exposures and physiological functions, and is subjected to external factors such as genetics, ethnicity, diet and environment.

It has been argued that the gold standard for assessing a drug’s anticholinergic effect remains the serum anticholinergic activity.\textsuperscript{58} However, a recent study found that clinical anticholinergic effects in patients were only partially associated with serum anticholinergic activity,\textsuperscript{18} adding to the complexity of defining an anticholinergic drug. Serum anticholinergic activity assays using peripheral blood may misrepresent anticholinergic effects centrally.

Similarly, in terms of sedative medications, universal definitions of what constitutes a sedative medication or a sedative load are lacking (Table 5). A review comparing four methods to quantify the effect of sedative medications on older people concluded that the usefulness of each method in clinical practice is yet to be determined.\textsuperscript{15} Pharmacological tools that are developed using various methods (Tables 4 and 5) should be applied to population settings originally described which investigated the outcomes they were designed to predict. Tools may be successively adapted according to medications available in the country investigated and revalidated in the new setting. This will more accurately reflect the impact of these medications on older adults in the setting investigated, but propose a challenge
to compare outcomes globally. Overall, an ideal pharmacological tool to investigate high-risk medication use in older adults in clinical practice should be accurate, reliable, easily accessible, easy-to-use, adaptable to the setting, based on current evidence, and provide evidence-based information that is consistently updated, to guide prescribing or drug withdrawal.

**Future: Drug Burden Index and deprescribing**

The term “deprescribing” has recently been discussed in the literature and describes the process of ceasing of unnecessary or harmful medications, especially in older adults. Deprescribing has been proposed as an important aspect of medication prescribing, monitoring, and use. The DBI, together with other scales, may have a clinical role in evaluating the medication load for a patient. Written reports of the evidence describing use of these high-risk medications and negative clinical outcomes can give prescribers the incentive to deprescribe inappropriate anticholinergic and sedative medications. Many studies have proposed use of single-active pharmacological scales in conjunction with medication review services, such as Medication Therapy Management or the Medication Management Initiative. Although this may facilitate action by health care professionals, such an approach focuses on anticholinergics or sedatives alone (and not in combination). A potential risk of this intervention is a shift from a patient-centered care approach when evaluating the benefits and risks of medications in older adults. While exposure to anticholinergic and sedative medications is associated with functional impairment in older adults, this does not dismiss other medication classes, such as anticoagulants, antiplatelets, and hypoglycemics, as high-risk.

**Conclusion**

In conclusion, as the proportion of older people in the global population grows, and the prevalence of polypharmacy, multimorbidity, and adverse outcomes associated with these increases, there are various pharmacological tools to guide health care professionals to manage medications. The DBI is a novel pharmacological evidence-based tool which measures an individual’s total exposure to anticholinergic and sedative medications and is strongly associated with functional impairment. Increasing DBI has been associated with poorer physical function, falls, frailty, hospitalization, and mortality (Figure 1). Future applications of the DBI include integration into practice through online software and prescribing tools, and incorporation into deprescribing studies. The DBI is one of many tools to guide prescribing in older adults, and has a specific role in measuring the functional burden of their medications. A patient-centered multidisciplinary approach to medication management, using multiple risk assessment tools combined with regular review of medication regimens, may provide the best approach to ensure the quality use of medicines for older people worldwide.

**Scenario resolution**

During Medication Therapy Management, the pharmacist conducted a comprehensive medication review. In the report...

---

For personal use only. Powered by TCPDF (www.tcpdf.org)
back to the primary care physician, the pharmacist reported a DBI of 1.6 (Table 1), which translates to a negative effect on physical function on this patient greater than that of three additional physical comorbidities. Furthermore, this patient was at a high risk of falls. The medication-related action plan included deprescribing temazepam, discussing non-pharmacological strategies for insomnia, reassessing the need for high-dose darifenacin and reducing the dose, and replacing the acetaminophen/codeine combination with acetaminophen alone, while monitoring the osteoarthritic pain. These were also outlined in the patient’s personal medication record. After one month, the dose of darifenacin was reduced and the codeine ceased. The patient’s dry mouth and fatigue had resolved and she reported improvement in her activities of daily living. While initially reluctant to withdraw temazepam, the patient was now considering this, following direct-to-patient education about the risks of benzodiazepine use\(^{81}\) and in view of the improvements she had already experienced after reducing her anticholinergic and sedative medication load.\(^{82}\)

## Disclosure

The authors report no conflicts of interest in this work.

## References

54. Hanlon JT, Schmader KE. The Medication Appropriateness Index at 20: where it started, where it has been, and where it may be going. Drugs Aging. 2013;30(11):893–900.